Shuangshuang Wu

Dr. Shuangshuang Wu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2015 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
WXWei Xu
Wei Xu
YWYunyan Wei
Yunyan Wei
SWShuangshuang Wu
Shuangshuang Wu
YWYun Wang
Yun Wang
ZWZhen Wang
Zhen Wang
JWJianqing Wu
Jianqing Wu
The T790M mutation of epithelial growth factor receptor (EGFR) is a major cause of the acquired resistance to EGFR tyrosine kinase inhibitor (EGFR-TKIs) treatment for lung cancer patients. The Hippo pathway effector, TAZ, has emerged as a key player in organ growth and tumorigenesis, including lung cancer.

17 April 2024 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
MJMinzi Ju
Minzi Ju
LYLu Yang
Lu Yang
GWGuowei Wang
Guowei Wang
FZFeng Zong
Feng Zong
YSYu Shen
Yu Shen
DYDecai Yu
Decai Yu
A chemicobiology toolbox for type I and type II photodynamic therapy.

13 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MZMingjiong Zhang
Mingjiong Zhang
JCJiahua Cui
Jiahua Cui
HCHaoyan Chen
Haoyan Chen
YCYifan Cheng
Yifan Cheng
QCQiaoyu Chen
Qiaoyu Chen
JWJianqing Wu
Jianqing Wu
Immune functions decline with aging, leading to increased susceptibility to various diseases including tumors. Exploring aging-related molecular targets in elderly patients with cancer is thus highly sought after. Here we find that an ER transmembrane enzyme, sterol O-acyltransferase 2 (SOAT2), is overexpressed in regulatory T (Treg) cells from elderly patients with lung squamous cell carcinoma (LSCC), while radiomics analysis of LSCC patients associates increased SOAT2 expression with reduced immune infiltration and poor prognosis. Mechanically, ex vivo human and mouse Treg cell data and in vivo mouse tumor models suggest that SOAT2 overexpression in Treg cells promotes cholesterol metabolism by activating the SREBP2-HMGCR-GGPP pathway, leading to enhanced Treg suppresser functions but reduced CD8+ T cell proliferation, migration, homeostasis and anti-tumor immunity. Our study thus identifies a potential mechanism responsible for altered Treg function in the context of immune aging, and also implicates SOAT2 as a potential target for tumor immunotherapy.

23 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MZMingjiong Zhang
Mingjiong Zhang
JCJiahua Cui
Jiahua Cui
HCHaoyan Chen
Haoyan Chen
YWYu Wang
Yu Wang
XKXingwang Kuai
Xingwang Kuai
SWShuangshuang Wu
Shuangshuang Wu
Background: Nicotinamide mononucleotide (NMN) is the physiological circulating NAD precursor thought to elevate the cellular level of NAD+ and to ameliorate various age-related diseases. An inseparable link exists between aging and tumorigenesis, especially involving aberrant energetic metabolism and cell fate regulation in cancer cells. However, few studies have directly investigated the effects of NMN on another major ageing-related disease: tumors. Methods: We conducted a series of cell and mouse models to evaluate the anti-tumor effect of high-dose NMN. Transmission electron microscopy and a Mito-FerroGreen-labeled immunofluorescence assay (Fe2+) were utilized to demonstrate ferroptosis. The metabolites of NAM were detected via ELISA. The expression of the proteins involved in the SIRT1–AMPK–ACC signaling were detected using a Western blot assay. Results: The results showed that high-dose NMN inhibits lung adenocarcinoma growth in vitro and in vivo. Excess NAM is produced through the metabolism of high-dose NMN, whereas the overexpression of NAMPT significantly decreases intracellular NAM content, which, in turn, boosts cell proliferation. Mechanistically, high-dose NMN promotes ferroptosis through NAM-mediated SIRT1–AMPK–ACC signaling. Conclusions: This study highlights the tumor influence of NMN at high doses in the manipulation of cancer cell metabolism, providing a new perspective on clinical therapy in patients with lung adenocarcinoma.

28 December 2023 in Chemical Science
Verified
Journal Article
Open access
PDF file
YGYa Gao
Ya Gao
AZAnwei Zhou
Anwei Zhou
KCKerong Chen
Kerong Chen
XZXinyuan Zhou
Xinyuan Zhou
YXYurui Xu
Yurui Xu
XNXinghai Ning
Xinghai Ning
A smart neutrophil neutralizer is developed for alleviating hyperinflammatory cytokine storm through simultaneously inhibiting multiple inflammatory pathways in macrophages.

15 May 2025 in Aging
Verified
Journal Article
Open access
PDF file
LCLei Chen
Lei Chen
HCHaoyan Chen
Haoyan Chen
QLQin Li
Qin Li
JMJun Ma
Jun Ma
YFYanzhi Feng
Yanzhi Feng
SWShuangshuang Wu
Shuangshuang Wu
Background: Both genetic and environmental factors can influence idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) development. The gut microbiota plays crucial roles in maintaining tissue homeostasis. Dysregulation of the gut microbiota can result in disease. However, whether the alteration of the gut microbiota influences IPF and COPD remains unknown. Research Question: What is the causal relationship between IPF, COPD and the gut microbiota-related metabolic pathways? What are the potential intermediate mediators in this relationship? Study Design and Methods: Intersect the gut microbiota and its metabolic pathways associated with IPF and COPD. Utilizing summary data from GWAS in public databases, a two-sample Mendelian randomization (MR) analysis was conducted on the gut microbiota-related metabolic pathway, the aspartate superpathway, in relation to IPF and COPD. Furthermore, we employed a two-step MR to quantify the proportion of influence mediated by monocytes and cDCs on the aspartate superpathway in relation to IPF and COPD. Results: The MR analysis found that the aspartate superpathway decreased the risk of developing IPF and COPD. Monocytes and cDCs acted as intermediary substances, participating in this with influence proportions of 7.88% and 6.27%, respectively. Interpretation: There is a causal link between the gut microbiota-related metabolic pathway, the aspartate superpathway, and IPF and COPD, where the influence is partially mediated by monocytes and cDCs. In clinical practice, we increase the focus on gut microbiota-mediated immune cells in relation to IPF and COPD.